Researchers have experimented with Ad5-based vaccines against a variety of infections for decades, but none are widely used. His team is developing an inhaled Ad5 COVID-19 vaccine, theorizing it could circumvent pre-existing immunity issues. “The Oxford vaccine candidate has quite an advantage” over the injected CanSino vaccine, he said. But they cautioned that HIV incidence should be monitored during and after trials of all Ad5-based vaccines in at-risk populations. “Demonstrating safety and efficacy of a vaccine is very important,” said Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J’s COVID-19 vaccine.

Source: Standard Digital September 01, 2020 07:18 UTC